What Are Thymosin Peptides? Origins, Types and Research

Thymosins are peptides first isolated from a calf thymus extract, and the two best known, thymosin alpha-1 and thymosin beta-4, turned out to be different molecules with different jobs.

Basics10 min read

Key takeaway

"Thymosin" began as the name of a thymus extract first described in 1966. A purified version, thymosin fraction 5, proved to be a mixture of many polypeptides. Thymosin alpha-1 has 28 amino acids and is the starting segment of a larger protein, prothymosin alpha. Thymosin beta-4 has 43 amino acids and binds actin inside most cells. No thymosin is FDA-approved.

At a glance

Article typeBasics
Main guideThymosin alpha 1 (Tα1): complete guide
Regulatory statusNot FDA-approved“It's not FDA-approved in the US” (Thymosin alpha 1 (Tα1): complete guide)
ClassImmune & inflammation
Body systemsImmune system
Studies cited10 in this article · 14 across 2 articles on Thymosin Alpha 1
Related productsBPC-157, TB-500 and thymic peptides

What are thymosin peptides is a question with a historical answer. The name comes from a 1960s thymus extract, not from a shared structure. Its best-known members, thymosin alpha-1 and thymosin beta-4, differ in length, origin and biology. Human trials of each have produced mixed results.

Quick answer: Thymosin peptides are a group of peptides first isolated from thymus extract. The two best known are thymosin alpha-1 and thymosin beta-4. They share a name but not a structure or a function. Neither is approved by the FDA. Published reviews report that thymosin alpha-1, as the drug thymalfasin, is approved in other countries.

What are thymosin peptides, and are they really peptides?

Yes. Thymosin alpha-1 and thymosin beta-4 are both peptides, short chains of amino acids. Vitrapep's guide to what peptides are explains the general category.

The group is defined by history, not by shared chemistry. "Thymosin" was first the name of a thymus extract. Researchers later separated that extract into many components and gave them Greek-letter names.

A shared name did not mean a shared role. One fraction 5 component, polypeptide beta-1, was inactive in the researchers' assays. Its sequence matched ubiquitin, a protein found throughout the body (Low and Goldstein, 1979). A 2007 review concluded that "none of the isolated peptides were really thymic hormones" (Hannappel, 2007).

Where did thymosin fraction 5 come from?

In 1966, Goldstein, Slater and White described the partial purification of a thymus factor they named thymosin (Goldstein et al., 1966). The title calls it a lymphocytopoietic factor, one that promotes production of lymphocytes, a type of white blood cell.

In 1972, the group traced the activity of bovine thymosin to what looked like a single protein of molecular weight 12,600. The preparation prolonged survival in mice whose thymus was removed at birth (Goldstein et al., 1972).

In 1977, the group sequenced thymosin alpha-1 from fraction 5 (Goldstein et al., 1977). By 1979, they described fraction 5 as a family of polypeptides with molecular weights from 1,000 to 15,000 (Low et al., 1979). Thymosin beta-4 followed in 1981 (Low et al., 1981).

Fraction 5 reached patients before its parts were known. In 1975, Wara and colleagues reported that it raised a lab marker of T cells in blood cells from people with immunodeficiency. One patient with an underdeveloped thymus then received it, and her marker rose to normal as she improved (Wara et al., 1975). This was a single-patient report, not a controlled trial.

How do thymosin alpha-1 and thymosin beta-4 compare?

Table 1 compares the two named peptides with the extract they came from. Formulas and weights come from PubChem entries for thymalfasin (CID 16130571) and thymosin beta-4 (CID 16132341).

Table 1

How do thymosin alpha-1 and thymosin beta-4 compare

FeatureThymosin fraction 5Thymosin alpha-1Thymosin beta-4
What it isPartly purified calf thymus extract containing many polypeptidesOne peptide of 28 amino acids, acetylated at the first residueOne peptide of 43 amino acids, acetylated at the first residue
Natural sourceThymus tissueThe first 28 residues of prothymosin alpha, a larger proteinMade by many cell types; found in blood, saliva, tears and wound fluid
SequenceNot applicable (a mixture)Ac-SDAAVDTSSEITTKDLKEKKEVVEEAENAc-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Molecular formulaNone (a mixture)C129H215N33O55C212H350N56O78S
Molecular weightComponents from 1,000 to 15,0003108.3 g/mol4963 g/mol
Drug name (USAN)NoneThymalfasinTimbetasin
Best-studied activityT-cell assays in animals and patient cellsImmune cell signaling (cell and animal studies)Binding single actin molecules inside cells
FDA statusNot approvedNot approvedNot approved
WADA 2026 listNot namedNot namedProhibited at all times (S2.3)

Both peptides start with an acetylated serine and aspartic acid, but their sequences then diverge.

How does thymosin alpha-1 work?

Thymosin alpha-1 is the starting segment of a bigger protein. In 1984, Haritos and colleagues isolated prothymosin alpha from rat thymus. It has about 112 amino acids, with the thymosin alpha-1 sequence at its start (Haritos et al., 1984).

The group found prothymosin alpha in rat brain, liver, kidney, lung and spleen, at 15% to 65% of thymus levels. They detected no free thymosin alpha-1. They proposed that it forms from prothymosin alpha while fraction 5 is prepared (Haritos, Tsolas and Horecker, 1984).

In a 2004 laboratory study, thymosin alpha-1 caused maturation of dendritic cells, which present foreign material to T cells. The effect ran through Toll-like receptor pathways, which sense microbial signals. In susceptible mice, it protected against a fungal lung infection (Romani et al., 2004). These are cell and mouse findings. The thymosin alpha-1 complete guide covers the peptide in more depth.

How does thymosin beta-4 work?

Thymosin beta-4 was first studied as a possible thymic hormone. Its 1981 sequence paper reported that it switched on an enzyme marker, terminal deoxynucleotidyl transferase, in mouse thymus cells (Low et al., 1981).

A decade later its main role turned out to be structural. Safer and colleagues showed that Fx, the peptide holding most unpolymerized actin in human platelets, was identical to thymosin beta-4. It forms a 1:1 complex with single actin molecules and blocks them from joining filaments (Safer et al., 1991). Actin filaments make up much of the cell's internal skeleton.

Beta-thymosins are now described as the main free-actin-holding peptides in most vertebrate cells. The same review notes that little is known about the mechanisms behind effects attributed to them outside cells (Hannappel, 2007). The thymosin beta-4 complete guide covers its animal and human research.

TB-500 is not the same molecule. FDA describes it as a synthetic, acetylated chain of seven amino acids matching residues 17 to 23 (LKKTETQ) of thymosin beta-4. FDA states that "thymosin beta-4 and TB-500 are not the same substance" (FDA, 2026). See the TB-500 complete guide.

What have human studies of thymosin peptides measured?

The largest thymosin alpha-1 trial, in sepsis, found no mortality benefit. A large thymosin beta-4 eye-drop trial posted results close to placebo.

Table 2

What have human studies of thymosin peptides measured

StudyPeptideDesign and populationMain resultEvidence level
Cohen et al., 1979Fraction 5 (called fraction V)Randomized; small-cell lung cancer during chemotherapy; size not given in abstractNo gain in complete responses; longer survival in one thymosin groupHuman randomized trial
Mutchnick et al., 1999Thymosin alpha-1Phase 3; 97 patients with chronic hepatitis B vs placeboComplete response 14% vs 4% (P = 0.084)Human randomized trial; not significant
Maio et al., 2010Thymosin alpha-1488 patients with metastatic melanoma in five groups, all given chemotherapy10 and 12 tumor responses in two thymosin arms vs 4 in control; survival 9.4 vs 6.6 months (P = 0.08)Human randomized trial
TESTS, Wu et al., 2025Thymosin alpha-1Phase 3; 1,106 adults with sepsis at 22 centers in China vs placebo28-day mortality 23.4% vs 24.1% (P = 0.93)Human randomized, double-blind trial
ARISE-3, NCT03937882Thymosin beta-4 eye drops (RGN-259)Phase 3; 700 adults with dry eye vs placeboCorneal staining change -0.41 vs -0.46 at day 15Human randomized trial; no test posted

The hepatitis B authors wrote that their results "do not confirm" efficacy reported in other clinical studies. In the melanoma trial, the survival difference was not statistically significant.

TESTS found "no clear evidence" that thymosin alpha-1 lowered 28-day mortality in adults with sepsis (Wu et al., 2025). Subgroup results by age and diabetes need confirmation. SciClone Pharmaceuticals, which licensed commercial rights to thymosin alpha-1 outside the US and Europe, was one of three funders (Tuthill, 2007). The paper says funders had no role in design, data collection or interpretation.

Trials continue. A ClinicalTrials.gov search on November 18, 2026 found 20 recruiting, upcoming or active studies of thymalfasin or thymosin alpha-1, mostly in China. One is a Phase 3 colorectal cancer trial with an estimated 2,500 participants (NCT05086614). Vitrapep's guide on how to find a peptide clinical trial explains registry statuses.

What side effects have thymosin trials reported?

No FDA label exists for any thymosin, so safety data come from trial reports. A trial that does not discuss side effects cannot be read as showing none.

In TESTS, adverse events through 90 days occurred in 66.4% of the thymosin alpha-1 group and 67.6% of the placebo group. Serious adverse events occurred in 26.8% and 29.3% (Wu et al., 2025). The most common events were anemia, fever, abdominal distension and coagulation disorders.

In the melanoma trial, adding thymosin alpha-1 to chemotherapy and interferon "did not lead to any additional toxicity" (Maio et al., 2010). The hepatitis B abstract does not describe side effects, and the early fraction 5 abstracts do not report adverse events.

In ARISE-3, no serious adverse events occurred in either group over about four weeks. Instillation-site pain was reported in 23 of 350 on RGN-259 and 16 of 349 on placebo (NCT03937882). These results reflect local eye exposure only.

FDA has also raised product-quality concerns. It said compounded thymosin alpha-1 "may pose significant risk for immunogenicity," meaning unwanted immune reactions. It also cited complexities with impurities and characterization (FDA, 2026). Vitrapep's page on research peptides and human-use risks covers these issues in general.

What is the regulatory status of thymosin peptides?

No thymosin is approved by the FDA. On November 18, 2026, openFDA searches of Drugs@FDA found no product containing thymalfasin, thymosin or timbetasin. Vitrapep keeps a list of FDA-approved peptide medicines.

A 2009 review said thymosin alpha-1 was approved in over 35 countries (Goldstein and Goldstein, 2009). It listed hepatitis B and C, and roles as an immune stimulant and adjuvant. The review did not list the countries. PubChem lists Zadaxin among its names.

In US compounding, a 2024 notice listed thymosin alpha-1 for discussion by FDA's Pharmacy Compounding Advisory Committee (Federal Register, 2024). FDA had placed it in category 2, for bulk substances that may present significant safety risks. FDA's page now lists it among nominations withdrawn by the nominators.

On October 30, 2026, HHS announced an interim enforcement policy covering six peptides used in compounding, including TB-500 (Federal Register, 2026). HHS said it does not intend to act against licensed pharmacies or physicians that compound them under set conditions, including a patient-specific prescription. Thymosin alpha-1 and full-length thymosin beta-4 are not on the list (HHS policy, Appendix A). See Vitrapep's summary of the October 2026 HHS policy.

The HHS notice states that compounded drugs are not FDA-approved. A research-use-only label does not make a product an approved drug or make use in people legal.

In sport, the WADA 2026 Prohibited List names "Thymosin-ß4 and its derivatives e.g. TB-500" under section S2.3, prohibited at all times (WADA, 2025). The list does not name thymosin alpha-1.

Frequently asked questions

What are thymosin peptides?

They are peptides first isolated from a calf thymus extract called thymosin fraction 5. The best known are thymosin alpha-1 and thymosin beta-4. They share a name, not a structure.

Are thymosins hormones of the thymus?

Not in the strict sense. Thymosin beta-4 is made by many cell types, and prothymosin alpha appears in several rat organs. A 2007 review concluded that none of the isolated peptides were really thymic hormones.

Is thymosin alpha-1 the same as thymosin beta-4?

No. Thymosin alpha-1 has 28 amino acids and comes from prothymosin alpha. Thymosin beta-4 has 43 amino acids and binds actin inside cells.

Is TB-500 a thymosin?

TB-500 is a synthetic copy of seven residues of thymosin beta-4. FDA states that the two are not the same substance.

Is any thymosin FDA-approved?

No. Drugs@FDA lists no thymosin product. Published reviews report that thymosin alpha-1, as thymalfasin, is approved in other countries.

Are thymosin peptides banned in sport?

WADA's 2026 list prohibits thymosin beta-4 and its derivatives, including TB-500, at all times. It does not name thymosin alpha-1.

What to know now

  • "Thymosin" is a historical label for peptides from a thymus extract, not a structural family.
  • Thymosin alpha-1 comes from prothymosin alpha; thymosin beta-4 binds actin in most cells.
  • The largest thymosin alpha-1 trial, in 1,106 adults with sepsis, found no clear effect on 28-day mortality.
  • No thymosin is FDA-approved. TB-500 is on the HHS October 2026 compounding policy list.

What we’re watching

  • Results from a US Phase 1 study of thymalfasin and vaccine response in older adults (NCT06821100).
  • The Phase 3 colorectal cancer trial of thymosin alpha-1 in China (NCT05086614), with primary completion estimated for March 2027.
  • FDA rulemaking on the 503A bulks list after the HHS October 2026 policy.

Also in the library

More for immune system

All 25 compounds for immune system

Sources: Goldstein 1966, Proceedings of the National Academy of Sciences of the United States of America, 56; Goldstein 1977, Proceedings of the National Academy of Sciences of the United States of America, 74; Low 1979, Journal of Biological Chemistry, 254; Low 1981, Proceedings of the National Academy of Sciences of the United States of America, 78; Haritos 1984, Proceedings of the National Academy of Sciences of the United States of America, 81; Safer 1991, Journal of Biological Chemistry, 266; Hannappel 2007, Annals of the New York Academy of Sciences, 1112; Wara 1975, New England Journal of Medicine, 292; Wu 2025, BMJ, 388; Maio 2010, Journal of Clinical Oncology, 28; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026; U.S. Department of Health and Human Services 2026, Federal Register, 91; World Anti-Doping Agency 2025. All 14 citations

Back to the research library

References

  1. Goldstein, A. L., Slater, F. D., & White, A. (1966). Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proceedings of the National Academy of Sciences of the United States of America, 56(3), 1010-1017. https://doi.org/10.1073/pnas.56.3.1010
  2. Goldstein, A. L., Low, T. L., McAdoo, M., et al. (1977). Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences of the United States of America, 74(2), 725-729. https://pubmed.ncbi.nlm.nih.gov/265536/
  3. Low, T. L., & Goldstein, A. L. (1979). The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin alpha1 and polypeptide beta1. Journal of Biological Chemistry, 254(3), 987-995. https://pubmed.ncbi.nlm.nih.gov/762108/
  4. Low, T. L., Hu, S. K., & Goldstein, A. L. (1981). Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proceedings of the National Academy of Sciences of the United States of America, 78(2), 1162-1166. https://pubmed.ncbi.nlm.nih.gov/6940133/
  5. Haritos, A. A., Goodall, G. J., & Horecker, B. L. (1984). Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Proceedings of the National Academy of Sciences of the United States of America, 81(4), 1008-1011. https://pubmed.ncbi.nlm.nih.gov/6583693/
  6. Safer, D., Elzinga, M., & Nachmias, V. T. (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry, 266(7), 4029-4032. https://pubmed.ncbi.nlm.nih.gov/1999398/
  7. Hannappel, E. (2007). beta-Thymosins. Annals of the New York Academy of Sciences, 1112, 21-37. https://doi.org/10.1196/annals.1415.018
  8. Wara, D. W., Goldstein, A. L., Doyle, N. E., & Ammann, A. J. (1975). Thymosin activity in patients with cellular immunodeficiency. New England Journal of Medicine, 292(2), 70-74. https://doi.org/10.1056/NEJM197501092920204
  9. Wu, J., Pei, F., Zhou, L., et al. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 388, e082583. https://doi.org/10.1136/bmj-2024-082583
  10. Maio, M., Mackiewicz, A., Testori, A., et al. (2010). Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. Journal of Clinical Oncology, 28(10), 1780-1787. https://doi.org/10.1200/JCO.2009.25.5208
  11. U.S. Food and Drug Administration. (2026). FDA briefing document: TB-500-related bulk drug substances (TB-500 (free base) and TB-500 acetate). Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. https://www.fda.gov/media/193349/download
  12. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  13. U.S. Department of Health and Human Services. (2026). Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Federal Register, 91, 68526-68527 (FR Doc. 2026-22192). https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  14. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf